Amgen sued over ‘withholding’ biosimilar information

17-02-2017

Amgen sued over ‘withholding’ biosimilar information

iko636 / iStockphoto.com

Amgen has been accused of withholding confidential information about its proposed biosimilar of Genentech’s cancer drug Avastin (bevacizumab).


BPCIA, biosimilar, Amgen, Genentech, FDA, patents, US District Court for the District of Delaware, confidential information

LSIPR